ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of “Moderate Buy” from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has earned an average recommendation of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $12.50.

Several analysts have recently commented on the company. UBS Group decreased their target price on ALX Oncology from $25.00 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 16th. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research report on Tuesday, November 12th. HC Wainwright reissued a “buy” rating and set a $25.00 price target on shares of ALX Oncology in a research note on Tuesday, August 13th. Lifesci Capital lowered shares of ALX Oncology from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 31st. Finally, Stifel Nicolaus reaffirmed a “hold” rating and set a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a report on Friday, August 9th.

Institutional Investors Weigh In On ALX Oncology

Institutional investors and hedge funds have recently modified their holdings of the business. CANADA LIFE ASSURANCE Co bought a new position in ALX Oncology in the first quarter valued at approximately $27,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company’s stock valued at $39,000 after purchasing an additional 5,200 shares during the period. Rhumbline Advisers boosted its position in shares of ALX Oncology by 10.8% in the 2nd quarter. Rhumbline Advisers now owns 55,220 shares of the company’s stock worth $333,000 after purchasing an additional 5,360 shares during the last quarter. AQR Capital Management LLC grew its stake in shares of ALX Oncology by 50.7% during the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company’s stock worth $109,000 after purchasing an additional 6,080 shares during the period. Finally, SG Americas Securities LLC increased its holdings in ALX Oncology by 33.6% in the third quarter. SG Americas Securities LLC now owns 27,394 shares of the company’s stock valued at $50,000 after purchasing an additional 6,888 shares during the last quarter. 97.97% of the stock is owned by institutional investors.

ALX Oncology Stock Up 1.3 %

NASDAQ ALXO opened at $1.51 on Thursday. The stock’s 50 day simple moving average is $1.56 and its 200 day simple moving average is $4.64. ALX Oncology has a one year low of $1.19 and a one year high of $17.83. The firm has a market cap of $79.64 million, a PE ratio of -0.51 and a beta of 1.03. The company has a debt-to-equity ratio of 0.07, a current ratio of 4.82 and a quick ratio of 4.82.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.